What to Expect During Routine Monitoring Visits in Clinical Trials
The primary purpose of RMVs is to:
Click to read the full article.
Routine Monitoring Visits
Scheduling and Frequency of Routine Monitoring Visits (RMVs) Across Clinical Trial Phases
Well-planned RMV schedules ensure:
Click to read the full article.
SDV and SDR During Routine Monitoring Visits: A Comprehensive Guide
SDV refers to the process of checking that the data recorded in Case Report Forms (CRFs) or Electronic Data Capture (EDC) systems accurately reflect the original source documents. CRAs (Clinical Research Associates) perform SDV to confirm that trial data is:
Click to read the full article.
Common Findings in RMVs and How to Resolve Them Effectively
The objective of an RMV is to confirm subject safety, data accuracy, and protocol compliance. CRAs act on behalf of sponsors and regulators like the EMA and USFDA, identifying gaps and deviations that may compromise trial validity or regulatory approval. Addressing RMV findings quickly ensures site quality and builds sponsor trust.
Click to read the full article.
CRA–Site Communication Best Practices During Monitoring Visits
Miscommunication during monitoring visits can result in delayed responses to queries, unresolved deviations, and non-compliance with sponsor expectations. Strong CRA–site communication fosters trust, increases protocol adherence, and prepares the site for audits and inspections from authorities like USFDA or MHRA.
Click to read the full article.
Using CTMS for RMV Tracking and Alerts in Clinical Trials
A CTMS is a centralized software tool used to manage operational aspects of clinical trials. It supports planning and documentation of monitoring visits, investigator site communications, subject enrollment metrics, and compliance logs. CTMS platforms serve as a bridge between clinical sites, monitors, and sponsors.
Click to read the full article.
RMV Preparation Checklist for Sites: How to Get Ready for a Monitoring Visit
Proper preparation can prevent findings, minimize delays, and build confidence with the sponsor. It demonstrates your site’s commitment to quality, subject safety, and data integrity. Regulatory agencies like USFDA and Health Canada often examine site readiness through CRA monitoring reports.
Click to read the full article.
How CRAs Document RMV Findings and Actions: A Monitoring Guide
Documentation ensures that every observation and decision made during an RMV is traceable and verifiable. Regulatory agencies like the USFDA and EMA emphasize clear, contemporaneous, and accurate monitoring records in accordance with ICH E6(R2) guidelines.
Click to read the full article.
Best Practices for Writing Monitoring Visit Reports (MVRs) in Clinical Trials
Many sponsors provide standardized monitoring report templates that align with their SOPs and Quality Management Systems (QMS). Tools like Clinical Trial Management Systems (CTMS) and eTMF platforms help in tracking visit findings and ensuring consistency. Templates from Pharma SOP templates are often used to streamline documentation.
Click to read the full article.
Addressing Protocol Deviations During Monitoring Visits
A protocol deviation is any change, divergence, or departure from the study protocol, Good Clinical Practice (GCP), or applicable regulatory requirements. Deviations can be categorized as:
Click to read the full article.